Alpine Immune Sciences Inc (ALPN) Expected to Announce Quarterly Sales of $310,000.00

Wall Street analysts forecast that Alpine Immune Sciences Inc (NASDAQ:ALPN) will report sales of $310,000.00 for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings. The lowest sales estimate is $300,000.00 and the highest is $320,000.00. Alpine Immune Sciences posted sales of $130,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 138.5%. The firm is expected to report its next quarterly earnings results on Wednesday, March 27th.

On average, analysts expect that Alpine Immune Sciences will report full year sales of $940,000.00 for the current year, with estimates ranging from $710,000.00 to $1.02 million. For the next fiscal year, analysts forecast that the business will post sales of $1.15 million, with estimates ranging from $1.00 million to $1.26 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative return on equity of 43.25% and a negative net margin of 1,602.19%.

Several research firms have issued reports on ALPN. Raymond James began coverage on Alpine Immune Sciences in a report on Monday, August 13th. They set a “buy” rating and a $13.00 price objective on the stock. Piper Jaffray Companies began coverage on Alpine Immune Sciences in a report on Thursday, September 27th. They set an “overweight” rating and a $12.00 price objective on the stock. Zacks Investment Research downgraded Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. ValuEngine downgraded Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Monday, November 12th. Finally, Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the stock a “buy” rating in a report on Monday, November 12th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $12.67.

NASDAQ:ALPN traded down $0.03 during trading hours on Thursday, hitting $4.80. 4,571 shares of the stock were exchanged, compared to its average volume of 10,059. Alpine Immune Sciences has a twelve month low of $4.51 and a twelve month high of $11.75. The company has a quick ratio of 9.20, a current ratio of 9.20 and a debt-to-equity ratio of 0.05.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Alpine Immune Sciences by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after purchasing an additional 11,200 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Alpine Immune Sciences by 20.9% in the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock valued at $927,000 after purchasing an additional 21,124 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Alpine Immune Sciences by 122.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 18,052 shares during the period. Finally, DRW Securities LLC lifted its stake in shares of Alpine Immune Sciences by 138.7% in the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 14,143 shares during the period. 56.82% of the stock is currently owned by institutional investors.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Story: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit